Crown Bioscience, Inc. is a platform technology company providing drug discovery and development services in the areas of Oncology and Inflammation.
CrownBio helps biopharmaceutical companies solve some of today's most pressing challenges in oncology with an offering of end-to-end preclinical solutions, a unique collection of ready-to-run, well-validated in vitro, in vivo, and ex vivo models, and cutting-edge technologies.
Our Translational Platforms bring clarity to drug discovery and enable clients around the world to deliver superior clinical candidates.
CrownBio provides preclinical immunotherapy research platforms to support the successful transition of immunotherapeutics from the lab into the clinic including models for the evaluation of CAR-T therapies, syngeneics, and humanized models.
Our team of experts worldwide, comprising highly trained PhD and MS scientists, provides services to Pharmaceutical, Biotechnology companies, and Biomedical Research Institutes around the world.
AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult eosinophilic asthma, and adult chronic rhinosinusitis with nasal polyps (CRSwNP).
In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
Chondrex, Inc. has been shaping the landscape of arthritis and inflammation research worldwide since 1996. Chondrex was initially focused on providing scientists with the tools necessary to study the pathogenesis of Rheumatoid Arthritis (RA) as well as to develop and screen potential therapeutics for RA. Over the past 20 years however, our scope has expanded beyond just RA research. We now offer a plethora of products ranging from collagen and monoclonal antibody reagents to a wide variety of assay kits for use in allergy, arthritis, connective tissue, and nephritis related research. One such product line, the Collagen Antibody-Induced Arthritis (CAIA) cocktails, allows for faster and more consistent dosage dependent induction of arthritis in mice than the Collagen Induced Arthritis (CIA) model. Furthermore, the CAIA model can be induced in almost all strains of mice, (including CIA-resistant, T-cell deficient, gene knockout, and transgenic mice) whereas the CIA model requires a restricted haplotype. Chondrex is committed to providing the highest quality and most reliable products in order to accelerate the rate of discovery in arthritis and inflammation research.
Cleveland HeartLab is a Clinical Reference Laboratory specializing in next-generation cardiovascular disease prevention, diagnosis and management.
Cleveland HeartLab offers a reliable and affordable group of biomarkers that provide additive and complimentary insight into an individual’s risk for heart disease and cardiac events. In particular, we have developed a unique profile of tests focused on managing and reducing inflammation, but also offer an array of standard and advanced tests that doctors can choose from.